Trials / Recruiting
RecruitingNCT06309966
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
A Phase 2/3 Multicenter, Randomization, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects With Refractory Focal Onset Epilepsy
- Status
- Recruiting
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 390 (estimated)
- Sponsor
- Biohaven Therapeutics Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BHV-7000 | BHV-7000 50 mg. Participants will take blinded investigational product (IP) once daily |
| DRUG | BHV-7000 | BHV-7000 75 mg. Participants will take blinded investigational product (IP) once daily |
| DRUG | Placebo | Matching placebo taken once daily |
Timeline
- Start date
- 2024-05-13
- Primary completion
- 2026-05-01
- Completion
- 2026-05-01
- First posted
- 2024-03-13
- Last updated
- 2026-04-17
Locations
174 sites across 16 countries: United States, Australia, Denmark, Finland, Germany, Greece, Hungary, India, Italy, Mexico, Poland, Portugal, Romania, Slovakia, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06309966. Inclusion in this directory is not an endorsement.